North America Computational Biology Market - By Tool, By Application, By Services, By End Use - Forecast, 2025 - 2034

North America Computational Biology Market Size

The North America computational biology market was estimated at USD 3.4 billion in 2024. The market is expected to grow from USD 3.8 billion in 2025 to USD 10.2 billion in 2034, at a CAGR of 11.8% during the forecast period, according to the latest report published by Global Market Insights Inc. The computational biology market is experiencing growth due to several key factors, including the rising adoption of computational designs in clinical trials, increasing drug development costs coupled with time constraints, growth in drug discovery and development, advancements in bioinformatics and data science, and supportive government policies.

Expansion of multiomics research, rising demand for personalized medicine, and use of computational tools in clinical trials and disease modeling are among the key factors fueling the market growth. The market is dominated by key players such as Thermo Fisher Scientific, Illumina Inc., QIAGEN, BIO-RAD Laboratories, and Dassault Systèmes. These key players are concentrating their efforts on AI-driven platforms, multi-omics data integration, scalable cloud-native solutions, and collaborative partnerships to accelerate drug discovery, improve predictive modeling, and facilitate personalized care.
 

The market reached from USD 1.8 billion in 2021 to USD 2.9 billion in 2023. The pandemic highlighted the importance of rapid genomic evaluations for real-time tracking of the virus and the development of vaccines. Since the COVID-19 pandemic, there has been ongoing development and investment in computational biology approaches for genomic surveillance, mutation tracking, and development of vaccines which is creating growth in both public health and pharmaceuticals.
 

In addition, AI and ML are also transforming the field of computational biology through predictive modeling, pattern recognition, and automation of data analyses. Therefore, the use of these technologies can allow researchers to optimize the accuracy and speed of biological simulation and the drug development pipeline.
 

The traditional process of developing pharmaceuticals is time-consuming and costly. For example, as per the published data, the average time required to bring a new drug to the market may take around 10-15 years of timespan and up to USD 2.6 billion as the development cost. This difficulty creates a need for tools in the field of computational biology that facilitate research and development protocols, reduce trial and error, and identify the most promising drug candidates early in the product development cycle. These tools are often used to model biological systems, model drug interactions, and analyze omics data, thereby significantly reducing lab experiments and minimizing clinical trial failures.
 

Moreover, collaborations between academic institutions, industry players, and government agencies are expected to further fuel industry growth. These partnerships drive innovation by combining academic research expertise, industry resources, and government support. Academic institutions contribute novel discoveries, companies provide funding and pathways to commercialization, and government agencies offer regulatory guidance and infrastructure. By leveraging collective knowledge and resources, these entities advance the development of computational biology tools, facilitate translational research, and help scientific innovations reach practical applications in healthcare and pharmaceuticals, thereby promoting market growth.
 

Computational biology is an interdisciplinary field combining algorithms, data analytics, and/or high-performance computing, with applications in modeling biological systems, analysis of complex biological data (genomics, proteomics), and speeding up drug discovery, disease modeling, and personalized medicine. The field is an integral part of modern life sciences and pharmaceutical research and development.
 

North America Computational Biology Market Trends

Emphasis on real-time genomic surveillance, growing adoption of digital twins in biology, and the rise of cloud-based bioinformatics platforms are among the key trends shaping the regional market growth.
 

• The area of computational biology is changing rapidly with cloud computing, utilizing a scalable, secure, and cost-effective infrastructure for researchers and companies to analyze and store its data. Researchers and companies can utilize advanced bioinformatics tools remotely and collaborate across institutions using large datasets and without the constraints of heavy investments in physical infrastructure. This trend reflects major innovations in better research momentum and lower cost barriers.
   
• Additionally, digital twins of biological systems are beginning to gain traction in drug development, disease modeling, and other applications within this domain. These allow researchers to test hypotheses, predict outcomes, and optimize therapies without the need for costly physical experiments or empirical data.
   
• Further, real-time genomics surveillance is critical to tracking infectious diseases and emerging variants. Computational biology technologies allow for quick sequencing, mutation analysis, and data sharing at an international scale. This trend has been accelerated by the COVID-19 pandemic and is now a standard part of most routine public health and global disease surveillance.
   

North America Computational Biology Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

In 2021, the market was valued at USD 1.8 billion and grew to USD 2.3 billion in 2022, reaching USD 2.9 billion by 2023. The growing adoption of advanced computational platforms and innovative solutions is playing a significant role in driving the industry's growth.
 

Based on tool, the North America computational biology market is segmented into analysis software and services, databases, and hardware. The analysis software and services segment accounted for a leading share of 43.4% in 2024. The rising demand for analysis software and services is fueled by the increasing volume of omics data, the need for sophisticated modeling tools, and the expanding use of AI-driven insights in drug discovery and precision medicine. The segment is expected to exceed USD 4.6 billion by 2034, growing at a CAGR of 12.2% during the forecast period.
 

• As biological data become more complex and are generated in very large amounts, the software and services segment is gaining strong momentum to handle it. Researchers and pharmaceutical companies want better analytical tools to interpret clinical, genomic, and proteomic data more quickly.
   
• These tools will allow a researcher to evaluate a hypothesis faster, develop predictive models, and visualize data effectively, all critical components of drug development and personalized medicine.
   
• Additionally, user-friendly interfaces, compliance with cloud computing, and software with AI capabilities are in demand, which promotes innovation and adoption in academia, healthcare, and biotech.
   
• In addition, the database segment was the second largest in 2024, valued at USD 1.2 billion. There has been a rise in the growth of biological databases, which allow researchers and companies to store and organize large and disparate amounts of genomic, proteomic, and clinical data in one central data store.
   
• Biological databases enable interoperability, data sharing, and access to information in real-time in a way that enhances collaborative research, regulatory submissions, and data-driven healthcare solutions.
   
• The hardware segment was valued at USD 703 million in 2024. There is a rising need for high-performance computing (HPC) hardware to accommodate the processing of complex biological simulations, large genomic sequencing efforts, and AI-based analyses.
   
• Moreover, as data generation increases, there is a need for scalable and efficient computing hardware infrastructure, including GPUs, cloud servers, and cloud computing and storage infrastructure to support real-time analyses and enhanced computational workflows for research and clinical projects.
   

Based on application, the North America computational biology market is segmented into cellular & biological simulation, drug discovery & disease modelling, preclinical drug development, clinical trials, and human body simulation software. The cellular & biological simulation segment accounted for a leading share and was valued at USD 1.2 billion in 2024.
 

• The cellular and biological simulation segment is driven by strong market demand for its ability to silico simulate complicated biological processes, reducing the need for highly expensive and labor-intensive lab experimentation.
   
• In addition, simulations are extremely valuable for understanding disease processes, drug interactions, and predicting responses in cells. With the rise of systems biology and personalized medicine, there is increased interest for many researchers and pharmaceutical companies to apply simulation tools to increase the speed of discovery, optimize therapeutic approaches, and reduce the costs of clinical development by facilitating preclinical modeling of disease.
   
• The drug discovery and disease modeling segment is projected to grow at a higher pace with a CAGR of 12.2% over the forecast period. It is growing at a robust growth rate as pharmaceutical companies are looking for faster and cost-effective methods for identifying candidate drugs.
   
• The use of virtual screening, target identification, and lead optimization in computational biology can be done to lower the time and resources required to conduct actual early-phase drug discovery R&D.
   
• Disease modeling can also be employed with AI and multiomic data to simulate disease development and treatment responses and is especially relevant for precision medicine initiatives.
   
• Further, the preclinical drug development segment was valued at USD 500.9 million in 2024. Computational biology is considerably being used to simulate pharmacokinetic, pharmacodynamic, and toxicity profiles for drug candidates in advance of or before actual patient studies.
   
• These tools can predict the response of a drug in a biological system and could cut down on the use of animal models in preclinical pharmacology studies and give a drug candidate a better chance of transitioning into clinical trials.
   
• Furthermore, the clinical trials segment is anticipated to record notable growth and reach USD 1.2 billion by 2034. Computational biology tools are useful for simulating biological responses, improving clinical trial design, and analyzing patient data more efficiently. These practices reduce clinical trial costs, add precision, and streamline regulatory approvals.
   

Based on services, the North America computational biology market is segmented into contract and in-house. The contract segment accounted for the majority market share of 56.8% in 2024 due to advantages such as cost-effective approach, access to advanced tools and expertise, etc.
 

• There is a significant demand for contract services as pharmaceutical and biotech companies move to contract organizations (CROs) and organizations that specialize in computational biology. This model gives organizations cost savings, advanced technology, and specialized talent while avoiding the overhead cost of building capabilities in-house.
   
• Contract organizations advocate for the adoption of computational biology models and tools, as they provide a range of benefits such as faster project completion, scalability, and flexibility, which is often an important variable for small to mid-sized organizations.
   
• Additionally, with drug development becoming increasingly complex, data-driven, and time-consuming, it is seen as a better strategy to promote innovation and lessen the burden of operations.
   
• The in-house segment was valued at USD 1.4 billion in 2024. In-house computational biology services within a pharmaceutical company or academic organization are necessary, especially when the organization wants full control of proprietary data and/or capabilities. Organizations engage in computational biology services to maintain data security and ownership of intellectual property and also to provide support for research and development activities in the future.
   
• Moreover, while in-house service can be substantially more expensive, it allows for a much higher degree of flexibility and interoperability with existing workflows, electronic medical record systems, etc.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the North America computational biology market is segmented into commercial and academics & research. The commercial segment accounted for the majority market share of 58.8% in 2024 due to growing adoption of such tools and solutions primarily in industrial settings.
 

• An increased number of pharmaceutical, biotechnology, and healthcare companies are beginning to take up computational biology at broader scales. These companies are using advanced modeling, simulations, and analytics to speed up drug discovery, reduce R&D expenditures, and develop personalized therapeutics more efficiently.
   
• Additionally, as companies look for ways to gain a competitive advantage, get their drugs to market faster, and have regulatory approval with less hindrance, the demand for computational biology grows.
   
• The academics & research segment was valued at USD 1.4 billion in 2024. The demand for computational biology solutions is largely driven by the advancements in genomics, systems biology, and molecular modeling in the academic and research arena. To handle complex biological data analysis, simulate biological processes, and share reproducible results, universities and research organizations depend on advanced software applications.
   
• Further, interdisciplinary studies that combine biology, computer science, and data science research are also growing and driving the demand. Additionally, increased government and private funding of life sciences research translates into more scientists using computational platforms and applications in the academic context.
   

Looking for region specific data?

Download Free PDF

The U.S. computational biology market was valued at USD 1.7 billion and USD 2.2 billion in 2021 and 2022, respectively. In 2024 the market size was valued at USD 3.2 billion from USD 2.7 billion in 2023. The significant focus on faster drug development processes by integrating advanced tools and frameworks is projected to fuel the market growth.
 

• The U.S. has become a frontrunner in computational biology owing to its robust biotech ecosystem, leading R&D capabilities, and public-private cooperation.
   
• Many of the largest pharmaceutical and technology companies are investing heavily in impactful areas, including AI-based drug development, genomics, and precision medicine. Research institutes and national laboratories are also significant contributors by playing a key role in advancing algorithms, data, and biological modeling.
   
• In addition, the U.S. has a favorable regulatory environment that increasingly supports the growth of digital health technologies. A talented workforce, advanced infrastructure, and culture of innovation are among the parameters that are expected to spur the country's growth and maintain its leading industry position.
   

Canada accounted for a substantial share in the North America computational biology market and was valued at USD 195.2 million in 2024.
 

• The demand for computational biology solutions is growing in Canada due to its excellent academic research environment, supportive government programs, and increasing life sciences industry.
   
• Universities and research institutes have started to adopt bioinformatics tools toward important developments in genomics, proteomics, and systems biology.
   
• The country’s growing emphasis on precision medicine and public health is also promoting the use of computational platforms to model diseases and develop therapeutics.
   
• Moreover, Canadian institutions and global biotech companies are increasingly collaborating to promote innovation, thereby establishing computational biology as a key part of Canada’s life sciences ecosystem.
   

North America Computational Biology Market Share

Leading companies operating in the market, such as Thermo Fisher Scientific, Illumina Inc., QIAGEN, BIO-RAD Laboratories, and Dassault Systèmes, among others, have a significant presence in the industry. These players maintain their key position by combining a strong product portfolio, regulatory clearances, consistent innovation, and partnerships with key stakeholders in the industry.
 

The North America computational biology is competitive and includes a combination of established biotech companies, emerging startups, academic institutions, and technology companies. Innovators within this space are focused on AI-optimized drug discovery, integration of multiple omics, and cloud-based bioinformatics platforms.
 

Additionally, numerous companies are pursuing strategic partnerships with universities and health systems to accelerate research and commercialization. Open-source and proprietary software are both in use, providing flexibility and scalability.
 

Moreover, newer companies are also ramping up and entering this market, including companies such as Schrödinger and Certara, to provide better advanced modeling and biosimulation methods as part of the pharmaceutical R&D process.
 

North America Computational Biology Market Companies

Few of the prominent players operating in the North America computational biology industry include:

• aganitha
• Atomwise
• Benevolent
• BIODIGITAL
• BIO-RAD
• cadence
• CERTARA
• compugen
• DASSAULT SYSTEMES
• deep genomics
• DNAnexus
• Genedata (Danaher)
• GINKGO
• Illumina
• instem
• QIAGEN
• Schrödinger
• Thermo Fisher SCIENTIFIC
   
• Thermo Fisher Scientific

Thermo Fisher Scientific held a leading position in the North America computational biology market with a share of around 12% in 2024. The company focuses on end-to-end integration across the life sciences value chain, combining R&D, manufacturing, diagnostics, and clinical services. Its strategy emphasizes aggressive mergers and acquisition, digital transformation, and AI-driven innovation to accelerate drug development and precision medicine. It also invests substantially in sustainability and regional expansion to maintain the key position.
 

• Illumina Inc.

Illumina is pivoting beyond sequencing into multiomics and AI-powered data interpretation. Company's new division, BioInsight, targets pharma partnerships for drug discovery using large-scale omics datasets. The company is expanding into proteomics (e.g., SomaLogic acquisition), enhancing clinical adoption, and driving innovation in single-cell and population-scale genomics.
 

• QIAGEN

QIAGEN’s strategy centers on its Sample to Insight model, offering integrated molecular diagnostics and life science tools. It focuses on high-growth platforms, while expanding its companion diagnostics and automation solutions. Strategic M&A, regional market penetration, and operational efficiency are key pillars of company's growth plan.
 

North America Computational Biology Industry News:

• In June 2025, Illumina, Inc. announced that it had entered into a definitive agreement with Standard BioTools to acquire SomaLogic. This development will enhance Illumina's presence in the growing proteomics market. It will aid the company in improving its industry presence.
   
• In December 2024, QIAGEN announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. This development enabled the company to enhance its service offering and improve the user experience through continuous advancement and updates.
   
• In November 2024, NVIDIA announced the availability of the open-source platform NVIDIA BioNeMo Framework to advance drug discovery and accelerate molecule design. This platform focuses on accelerating and scaling digital biology for different stakeholders in the industry.
   
• In April 2024, Seed Health, a microbiome science company, launched its CODA platform, which is powered by the Human Phenotype Project, a comprehensive multi-omics data set. CODA is a computational biology platform for the discovery and development of next-generation precision probiotics and microbiome-directed interventions. This product launch is expected to allow the company to further improve its industry presence.
   

The North America computational biology market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Tool

• Analysis software and services
• Databases
• Hardware

Market, By Application

• Cellular & biological simulation
  • Computational genomics
  • Computational proteomics   
  • Pharmacogenomics
  • Other simulations
• Drug discovery & disease modelling
  • Target identification
  • Target validation
  • Lead discovery
  • Lead optimization
• Preclinical drug development
  • Pharmacokinetics
  • Pharmacodynamics
• Clinical trials
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
• Human body simulation software

Market, By Services

• Contract
• In-house

Market, By End Use

• Commercial
• Academics & research

The above information is provided for the following countries:

• U.S.
• Canada